{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:21:13Z","timestamp":1760235673340,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) is characterized by the presence of \u03b2-amyloid plaques and neurofibrillary tangles, while Lewy body dementia (LBD) is characterized by \u03b1-synuclein (\u03b1-syn) inclusions. Some authors examine \u03b1-syn protein in the neurodegeneration process of AD and propose to consider cerebrospinal fluid (CSF) \u03b1-syn as a possible additional biomarker to the so-called \u201ccore\u201d of AD. Objective: To determine whether there is a correlation between \u03b1-syn levels and \u201ccore\u201d AD biomarkers in patients with mild cognitive impairment (MCI). Materials and methods: In total, 81 patients in the early stages of MCI were selected from the outpatient dementia consultation in Alicante General Hospital. Using a cross-sectional case\u2013control design, patients were analyzed in four groups: stable MCI (MCIs; n = 25), MCI due to AD (MCI-AD; n = 32), MCI due to LBD (MCI-LBD; n = 24) and a control group of patients with acute or chronic headache (Ctrl; n = 18). Correlation between CSF protein levels in the different groups was assessed by the Rho Spearman test. Results: We found positive correlations between T-tau protein and \u03b1-syn (\u03c1 = 0.418; p value &lt; 0.05) and p-tau181p and \u03b1-syn (\u03c1 = 0.571; p value &lt; 0.05) exclusively in the MCI-AD group. Conclusion: The correlation found between \u03b1-syn and tau proteins in the first stages of AD support the involvement of \u03b1-syn in the pathogenesis of AD. This result may have clinical and diagnostic implications, as well as help to apply the new concept of \u201cprecision medicine\u201d in patients with MCI.<\/jats:p>","DOI":"10.3390\/medicina57090954","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T21:45:57Z","timestamp":1631483157000},"page":"954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"57","author":[{"given":"Victoria","family":"Monge-Garc\u00eda","sequence":"first","affiliation":[{"name":"Rehabilitation Service, University General Hospital of Alicante, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-9752","authenticated-orcid":false,"given":"Mar\u00eda-Salud","family":"Garc\u00eda-Ayll\u00f3n","sequence":"additional","affiliation":[{"name":"Research Unit, University General Hospital of Elche, FISABIO, 03456 Elche, Spain"},{"name":"Instituto de Neurociencias de Alicante, Miguel Hern\u00e1ndez-CSIC, San Juan de Alicante, 03550 Alicante, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), San Juan de Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"S\u00e1ez-Valero","sequence":"additional","affiliation":[{"name":"Research Unit, University General Hospital of Elche, FISABIO, 03456 Elche, Spain"},{"name":"Instituto de Neurociencias de Alicante, Miguel Hern\u00e1ndez-CSIC, San Juan de Alicante, 03550 Alicante, Spain"},{"name":"Institute of Sanitary and Biomedical Research of Alicante (ISABIAL), 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"S\u00e1nchez-Pay\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Sanitary and Biomedical Research of Alicante (ISABIAL), 03010 Alicante, Spain"},{"name":"Preventive Medicine Service, University General Hospital of Alicante, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Navarrete-Rueda","sequence":"additional","affiliation":[{"name":"Instituto de Neurociencias de Alicante, Miguel Hern\u00e1ndez-CSIC, San Juan de Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Manzanares-Robles","sequence":"additional","affiliation":[{"name":"Instituto de Neurociencias de Alicante, Miguel Hern\u00e1ndez-CSIC, San Juan de Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Gasparini-Berenguer","sequence":"additional","affiliation":[{"name":"Neurology Department, University General Hospital of Alicante, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Romero-Lorenzo","sequence":"additional","affiliation":[{"name":"Neurology Department, University General Hospital of Alicante, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Angeles","family":"Cort\u00e9s-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Instituto de Neurociencias de Alicante, Miguel Hern\u00e1ndez-CSIC, San Juan de Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-7699","authenticated-orcid":false,"given":"Jos\u00e9-Antonio","family":"Monge-Argil\u00e9s","sequence":"additional","affiliation":[{"name":"Institute of Sanitary and Biomedical Research of Alicante (ISABIAL), 03010 Alicante, Spain"},{"name":"Neurology Department, University General Hospital of Alicante, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/JAD-130458","article-title":"\u03b1-Synuclein in Cerebrospinal Fluid of Alzheimer\u2019s Disease and Mild Cognitive Impairment","volume":"36","author":"Korff","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","article-title":"Increased CSF \u03b1-synuclein levels in Alzheimer\u2019s disease: Correlation with tau levels","volume":"10","author":"Slaets","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-016-0706-0","article-title":"Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer\u2019s disease, mild cognitive impairment, or healthy controls: A two year follow-up study","volume":"16","author":"Berge","year":"2016","journal-title":"BMC Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00415-016-8259-0","article-title":"Cerebrospinal \u03b1-synuclein in \u03b1-synuclein aggregation disorders: Tau\/\u03b1-synuclein ratio as potential biomarker for dementia with Lewy bodies","volume":"263","author":"Llorens","year":"2016","journal-title":"J. Neurol."},{"key":"ref_5","first-page":"1","article-title":"Differential role of CSF fatty acid binding protein 3, \u03b1-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia","volume":"9","author":"Chiasserini","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jalz.2018.02.015","article-title":"Cerebrospinal fluid \u03b1-synuclein contributes to the differential diagnosis of Alzheimer\u2019s disease","volume":"14","author":"Shi","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3233\/JAD-171013","article-title":"A Longitudinal Study of Total and Phosphorylated \u03b1-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer\u2019s Disease and Mild Cognitive Impairment","volume":"61","author":"Wang","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_8","first-page":"1","article-title":"Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer\u2019s disease and dementia with Lewy bodies from the prodromal stage","volume":"12","author":"Bousiges","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_9","first-page":"1","article-title":"CSF total tau\/\u03b1-synuclein ratio improved the diagnostic performance for Alzheimer\u2019s disease as an indicator of tau phosphorylation","volume":"12","author":"Shim","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012","article-title":"Soluble -Synuclein Is a Novel Modulator of Alzheimer\u2019s Disease Pathophysiology","volume":"32","author":"Larson","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between A\u03b2, Tau, and -Synuclein: Acceleration of Neuropathology and Cognitive Decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jalz.2018.06.3053","article-title":"Association of cerebrospinal fluid \u03b1-synuclein with total and phospho-tau181protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer\u2019s disease biomarkers","volume":"14","author":"Vergallo","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","article-title":"CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer\u2019s disease","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000096287","article-title":"Revised criteria for mild cognitive impairment: Validation within a longitudinal population study","volume":"22","author":"Artero","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.neurobiolaging.2015.05.003","article-title":"Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study","volume":"36","author":"Kruse","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jnc.14719","article-title":"Measurement of CSF \u03b1-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease","volume":"150","author":"Navarrete","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00401-018-1895-y","article-title":"Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease","volume":"136","author":"Pace","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03033329","article-title":"The neurotoxin, MPP+, induces hyperphosphorylation ofTau, in the presence of \u03b1-Synuclein, in SH-SY5Y neuroblastoma cells","volume":"10","author":"Duka","year":"2006","journal-title":"Neurotox. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"\u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies","volume":"33","author":"Msc","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"117957352090739","DOI":"10.1177\/1179573520907397","article-title":"Current and Future Treatments in Alzheimer Disease: An Update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Central Nerv. Syst. Dis."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/954\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:47Z","timestamp":1760166047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090954"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090954","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}